Sign Out
Ribociclib (Kryxana) is (a cyclin-dependent kinase inhibitor, CDKi) indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (locally) advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant.
In pre- or perimenopausal women, or men, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
